Andres Forero, MD

 
Rank:

Professoraforero 

Division:
Hematology & Oncology

Campus Address: NP 2510

Mailing Address: 
1720 2nd Avenue South, NP2540
Birmingham, AL 35294-3300

Phone: 205-934-7167

Email: aforero@uabmc.edu


For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816. 


Departmental Affiliation(s):
Primary: Medicine

Biosketch:

A. PERSONAL STATEMENT

I returned to the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) from Colombia in 2000 in order to pursue translational research with an emphasis on early clinical trials linked to laboratory observations in Breast Cancer and Lymphomas. Fortunately, upon my return I was able to continue working with my lifetime mentor, Dr. Albert F. LoBuglio, and received a K12 Individual Mentored Career Development Award sponsored by NCI, which provided me a major impetus to establishing my career as a clinical investigator with strong laboratory components to my research efforts. Additionally, I completed the K30 Clinical Research Training Program, a two-year course sponsored by the NCI that gave me the tools necessary to understand translational research. Over the past 10 years I have been the Director of the Clinical Protocols and Data Management Shared facility of the UAB CCC, I developed the first DSMP of the UAB CCC, I have led a large number of clinical trials (Investigator Initiated and Industry trials including studies holding INDs) with emphasis on early pilot, phase I and II studies, I have participated actively in the development and implementation of different projects through the Breast SPORE, and in my leadership role I led the team of investigators that developed the Susan G. Komen for the Cure Promise Grant which has 4 different projects (6.4 million dollars over 5 years). Over the last 8 years I have been the Principal Investigator of two translational research projects which have the potential to change and/or improve the standard of care management in breast cancer (Dual Pathway Target Inhibition in Breast cancer: ER and VEGF and Targeting Death Receptors for Treatment of Triple Negative Breast Cancer).

B. POSITIONS

1990-1991 Instructor, Physical Diagnosis Course, Department of Medicine, UAB

1991-1997 Assistant Professor, Department of Medicine, Division of Hem/Onc, Javeriana University School of Medicine, Bogotá, Colombia

1992-1995 Director of Clinical Oncology, Colombian NCI, Bogotá, Colombia

1992-2000 Founding Member and Co-Director, Colombian Bone Marrow Transplant Program, Colombian NCI/Marly Clinic, Bogotá, Colombia

1992-2000 Director, Division of Hem/Onc, Javeriana University Cancer Center, Bogotá, Colombia

1998-2000 Associate Professor, Department of Medicine, Division of Hem/Onc, Javeriana University School of Medicine, Bogotá, Colombia

2000-2001 Research Assistant Professor, Department of Medicine, Division of Hem/Onc; UAB

2000-2006 Associate Scientist, UAB CCC

2000-Present Director, Protocol/Data Management Shared Facility, UAB CCC

2000-2004 Co-Chairman, Clinical Trials Review Committee, UAB CCC.

2001-2006 Assistant Professor, Department of Medicine, Division of Hem/Onc; UAB

2004-2010 Associate Scientist, Minority and Health Disparities Research Center, UAB

2010-Present Scientist, Minority and Health Disparities Research Center, UAB

2004-2005 Chairman, Clinical Trials Review Committee, UAB CCC

2005-Present Co-Chairman, Clinical Trials Review Committee, UAB CCC

2005-Present Chairman, Clinical Trials Monitoring Committee, UAB CCC

2006-2010 Associate Professor, Department of Medicine, Division of Hem/Onc; UAB

2006-Present Scientist, UAB CCC

2010-Present Program Co-Leader, Experimental Therapeutics, UAB CCC

2010-Present Professor, Department of Medicine, Division of Hem/Onc; UAB

2012-Present The O'Neal-Sokol Breast Cancer Research Foundation of Alabama Endowed Professorship, UAB

C. AWARDS and HONORS

(1) Best Abstract in Clinical Research, Colombian Society of Hematology and Clinical Oncology Annual Meeting, Colombia, 1993; (2) Best Abstract in Clinical Cancer Research, Colombian Cancer Society Annual meeting, Colombia, 1997; (3) Henri Horoszowski Memorial Prize for the Best Orthopedic Presentation, International Society of Hemophilia, 1998; (4) Outstanding Teacher, University of Alabama at Birmingham, Division of Hematology/Oncology, Fellowship Training Program, 2003-2004; (5) Judge for the Oncology Competition; Southern Society for Clinical Investigation Oncology Young Investigator's Forum New Orleans, Louisiana; 2007; (6) Appointed as one of the Best Doctors in Alabama, 2007, 2008, 2009; (7) Elected to the Southern Society of Clinical Investigation, 2007; (8) Susan G. Komen for the Cure – 2008 Komen Promise Grant #1; 2008 Scientific Peer Review Meeting; Scientist Reviewer, Washington, March 2008; (9) Distinguished Board Member 2009 – The Breast Cancer Research Foundation of Alabama; (10) The Albert F. LoBuglio Distinguished Faculty Award 2009 (bestowed to a faculty member who has made distinguished contributions to the research activities of the Cancer Center); (11) Appointed as one of the Best Doctors in America and America's Top Doctors for Cancer, 2010; (12) Congressionally Directed Medical Research Program on Era of Hope Scholars in Breast Cancer 2010; Scientific Peer Review Meeting; Scientist Reviewer, Washington, April 2010.

D. COMMITTEES

1992-1997, Board Member, Colombian Research Group in Gastric Carcinoma; 1992-Present, Member, Medical Advisory Committee, Colombian Cancer Society; 1995-2000, Oncology Consultant and Investigator, Bristol Myers Squibb-Colombia; 1995-2000, Principal Investigator, Taxotere in the Treatment of Breast Carcinoma, National Cancer Institute; 1997-1999, Board Member, Colombian Cancer Society; 1998-2001, Board Member of GOL (Latin American Oncology Research Group); 2003-2009, Member, Non-Hodgkin's Lymphoma panel, National Comprehensive Cancer Network (NCCN) (National Level); 2003-2005, Member, Cancer Committee of UAB Health System; 2004-2009, Member, Hodgkin's Lymphoma panel, National Comprehensive Cancer Network (NCCN) (National Level); 2005-Present, Founding Member, The Translational Breast Cancer Research Consortium (National Level); 2006-Present, Member of the DSMB for the Phase II/III trial of Lumiliximab with or without FCR in patients with previously untreated CLL (International Level); 2007-Present, Founding member, Lymphoma Research Consortium (National Level; 2007-Present, Board Member, Breast Cancer Research Foundation of Alabama (State Level); 2008-Present, Member, Triple Negative Breast Cancer Working Group – Translational Breast Cancer Research Consortium (National Level); 2008 – 2010, Member, Operational Efficiency Working Group of the Clinical Trials Advisory Committee, National Cancer Institute (National Level); 2009-Present, Member, Breast Cancer Panel, National Comprehensive Cancer Network (NCCN) (National Level).

E. SOCIETIES (Selected)

American Society of Clinical Oncology, Member
American Society of Hematology, Member
Southern Society of Clinical Investigation, Member

Clinical Interests
Breast Cancer and Lymphomas
Targeted Therapy

Selected Publications
1.Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF: A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 18:751-759, 2003. Investigator Initiated Protocol.
2.Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF: Phase I trial of a novel anti-CD20 non-Hodgkin lymphoma. Blood 104:227-236, 2004. (Cover Page, July 1, 2004 Issue). Investigator Initiated Protocol.
3.Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF: Pretargeted® radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 20:379-390, 2005. Investigator Initiated Protocol.
4.Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F: Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 20:467-478, 2005. Investigator Initiated Protocol.
5.Triozzi P, Shah J, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry M, LoBuglio AF, Forero A: Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity (ADCC). Cancer Biother Radiopharm 21; 6: 553-559, 2006. Investigator Initiated Protocol.
6.Forero A, Shah J, Carlisle R, Triozzi P, LoBuglio A, Wang WQ, Fujimori M, Conry M: A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 21; 6:561-568, 2006. Investigator Initiated Protocol.
7.Forero-Torres A, Saleh MN: Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Clinical Lymphoma Myeloma 8 (1): S13-7, 2007.
8.Shah J, Wang W, Harrough D, Seville W, Meredith R, Shen S, Mueh J, Lister J, Jasthy S, Magas G, Mckay C, Krumdieck R, Tharp M, Winter C, Gregory M, Buchholz W, Awasthi S, Jacobs S, Cheng H, Egner J, LoBuglio AF, Forero A: Retreatment with Yttrium 90 Ibritumomab Tiuxetan in Patients with B-Cell Non Hodgkin's Lymphoma. Leukemia and Lymphoma 48 (9): 1736-1744, 2007.
9.Meredith RF, Shen S, Forero-Torres A, LoBuglio AF: A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med 49:279-284, 2008. Investigator Initiated Protocol.
10.Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL and Gopal AK: A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology 146: 171-179, 2009.
11.Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 27 (26): 4371-4377, 2009.
12.Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, LoBuglio AF: Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin's Lymphoma. Journal of Nuclear Medicine 2010; 51 (1): 150-157, 201. Investigator Initiated Protocol.
13.Furman R, Forero A, Shustov A, Drachman J: A Phase I Study of Dacetuzumab (SGN-40, a HumanizedAnti-CD40 Monoclonal Antibody) in Patients with Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 2010; 51 (2): 228-235.
14.Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo F, Wojtowicz-Praga S, Percent I, Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals 2010; 25 (1): 13-19. (Investigator Initiated Protocol).
15.Forero-Torres A, Saleh M, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith R, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF: A pilot trial of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive breast cancer. In Press 2010, Clinical Breast Cancer 2010; 10(4): 275-280. (Investigator Initiated Protocol).
16.Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, and Forero-Torres A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363:1812-1821 (Senior Author).

Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.